Literature DB >> 6189855

Regulation of natural killer cell cytotoxicity by prostaglandin E in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases. Part 1. Association between amount of prostaglandin produced, natural killer, and endogenous interferon.

J E Merrill, R H Gerner, L W Myers, G W Ellison.   

Abstract

MS patients' peripheral blood mononuclear cells (MNC) spontaneously produced more prostaglandin E1&2 (PGE) in vitro than did OND or normal control MNC correlating with lower levels of NK activity and endogenous interferon (IFN) production while there were no differences between OND and normal controls. MS neat CSF contained significantly higher levels of measurable PGE with concomitantly lower NK activity and % IFN-positive cells than was seen in OND CSF. The PGE producing cells were depleted in the nylon wool-passed (NWP) and enriched in the nylon wool-adherent (NWAd) populations in direct correlation with depletion and enrichment of esterase-positive monocyte/macrophages, respectively, suggesting that at least some of the PGE-producing cells were adherent monocyte/macrophages. At 24 and 48 h after stimulation with PHA, MS unfractionated MNC produced significantly more PGE than OND and normal MNC; at 24 and 72 h, MS NWAd cells produced significantly more PGE than normals and ONDs. MS and ONDs produced the same amount of PGE at 48 h in the stimulated NWAd fraction.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6189855     DOI: 10.1016/0165-5728(83)90037-1

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  10 in total

1.  Lipoic Acid Stimulates cAMP Production in Healthy Control and Secondary Progressive MS Subjects.

Authors:  Sarah E Fiedler; Vijayshree Yadav; Amelia R Kerns; Catherine Tsang; Sheila Markwardt; Edward Kim; Rebecca Spain; Dennis Bourdette; Sonemany Salinthone
Journal:  Mol Neurobiol       Date:  2017-11-15       Impact factor: 5.590

Review 2.  The role of prostaglandins in altered leukocyte function in multiple sclerosis.

Authors:  P Dore-Duffy; S Y Ho; M Longo
Journal:  Springer Semin Immunopathol       Date:  1985

3.  Expression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: effect of glatiramer acetate (copolymer 1).

Authors:  R Balabanov; D Lisak; T Beaumont; R P Lisak; P Dore-Duffy
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

4.  Spinal fluid lymphocytes responsive to autologous and allogeneic cells in multiple sclerosis and control individuals.

Authors:  G Birnbaum; L Kotilinek; M Schwartz; M Sternad
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

5.  Double blind study of intrathecal beta-interferon in multiple sclerosis: clinical and laboratory results.

Authors:  C Milanese; A Salmaggi; L La Mantia; A Campi; M Eoli; M Savoiardo; G Bianchi; A Nespolo
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-07       Impact factor: 10.154

6.  In vitro study of mediators of inflammation in multiple sclerosis.

Authors:  J E Merrill; S R Strom; G W Ellison; L W Myers
Journal:  J Clin Immunol       Date:  1989-03       Impact factor: 8.317

Review 7.  Autoimmune disease and the nervous system. Biochemical, molecular, and clinical update.

Authors:  J E Merrill; M C Graves; D G Mulder
Journal:  West J Med       Date:  1992-06

8.  Natural cytotoxic activity in multiple sclerosis patients: defects in IL-2/interferon gamma-regulatory circuit.

Authors:  E Braakman; A van Tunen; A Meager; C J Lucas
Journal:  Clin Exp Immunol       Date:  1986-11       Impact factor: 4.330

Review 9.  Multiple sclerosis: neuroimmunologic puzzle.

Authors:  B P Barna
Journal:  Clin Lab Med       Date:  1986-03       Impact factor: 1.935

10.  Regulation of astrocyte proliferation by prostaglandin E2 and the alpha subtype of protein kinase C.

Authors:  M Sawada; A Suzumura; K Ohno; T Marunouchi
Journal:  Brain Res       Date:  1993-06-04       Impact factor: 3.252

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.